Merck (MRK) EVP David Maraldo Exercises Options, Sells Shares

What Happened
David R. Maraldo, Executive Vice President & President, Merck MMD, exercised three option grants and immediately sold the resulting shares on August 5, 2026. He exercised 6,311 shares at $73.73 (cost $465,310), 9,709 shares at $87.10 (cost $845,654), and 2,686 shares at $84.71 (cost $227,531) — total exercise cost about $1,538,495. All 18,706 shares were sold in the open market at a weighted average price of $128.72 for aggregate proceeds of $2,407,797. The transactions appear to be a cashless exercise (exercise followed by immediate sale).

Key Details

• Transaction date: August 5, 2026. Sale weighted average price: $128.72 (per footnote range $128.64–$128.85).
• Shares exercised (acquired): 18,706 total (6,311; 9,709; 2,686). Exercise costs totaled ~$1.54M.
• Shares sold (disposed): 18,706 total; proceeds ~$2.41M. Net cash gain (proceeds minus exercise cost) ≈ $869,302.
• Shares owned after the transactions: Not specified in the provided excerpt of the filing. Check the full Form 4 for post-transaction holdings.
• Footnotes: F1 notes the sale price is a weighted average across multiple trades ($128.64–$128.85). F2–F4 describe the vesting schedules for the underlying option grants (vesting in three equal installments on the dates listed).
• Filing timeliness: Report filed Aug 7, 2026 for transactions on Aug 5, 2026 (no late-filings flag indicated in the provided data).

Context

• This was an option exercise followed by an immediate open-market sale (a common way executives realize value from vested options). Such transactions typically reflect option exercise and routine disposition rather than a direct buy signal for shareholders.
• The filing shows derivative transactions (code M for exercise) and corresponding sales (code S); the $0.00 entries reflect the technical disposition/transfer of the derivative instrument on exercise.
• No indication in the provided excerpt of a Rule 10b5-1 trading plan, gift, or 10% owner status.